ArticleThe Lancet regional health. Southeast Asia2026
Virologic outcomes on Dolutegravir-based therapy among children and adolescents living with HIV in Thailand: findings from a national registry database.
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is recommended for initial and subsequent ART for children and adolescents living with HIV (CALHIV). We evaluated virologic outcomes after starting DTG-based ART using the National AIDS Program (NAP) database in Thailand. Methods: We conducted a cohort study including CALHIV aged <18 years at DTG start, with at least one viral load (VL) measurement after starting DTG-based ART. Outcomes were: (i) viral suppression (VS) (defined as VL < 1000 and <50 copies/mL), (ii) episodes of viremia (≥1 VL ≥ 1000 copies/mL), and (iii) among those with ≥2 VL measurements, confirmed virologic failure (VF) (two consecutive VL ≥ 1000 copies/mL). Cox regression models were used to assess factors associated with viremia and VF, and generalized estimating equations models to assess factors associated with rates of viremia over time. Findings: Of 2395 CALHIV included, 49% were female and 69% were ART-experienced at DTG start. Median age at DTG start was 15 years (Interquartile range [IQR] 12-17). Over a median 1.55 years [1.05-1.92] on DTG and a median of 2 [1-2] VL measurements per participant, 84.3% had VS < 1000 copies/mL and 75.9% <50 copies/mL throughout follow-up; 15.7% experienced viremia. Among those with ≥2 VL measurements available, 7.1% had confirmed VF. In adjusted models, female sex and being ART-experienced with detectable VL at DTG start were associated with a significantly higher risk of viremia and VF. Rates of episodic viremia increased over time and varied by age, with higher rates among those aged < 6 years and 12-15 years at DTG start compared to children aged 6-<12 year. Interpretation: Most CALHIV achieved viral suppression on DTG. Overall risk of virologic failure was low but was substantially higher among ART-experienced individuals with detectable VL at DTG start, underscoring the importance of close monitoring and targeted adherence support for vulnerable subgroups. Funding: Kasetsart University Research and Development Institute, Kasetsart University, Thailand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.